Real-world experience with sorafenib for advanced Hepatocellular Carcinoma (HCC) in a Scottish Population


Session type:

Adam Peters1



Sorafenib is the current standard of care in patients with advanced hepatocellular carcinoma (HCC).

We set out to determine whether the experience in a cohort of patients in the West of Scotland was consistent with the pivotal SHARP study that reported a median duration of sorafenib treatment of 5.3 months (m) and median overall survival (OS) of 10.9 months.


A retrospective review of electronic prescribing records at our institution identified all patients prescribed sorafenib from November 2016 to October 2017. We collected patient demographics, as well as tumour marker data, treatment duration and outcome. Data was analysed using SPSS software.


55 patients received sorafenib in the time period - 46 (84%) were male and 9 (16%) female. The median age was 68 (95% CI: 57.7-78.3). All patients were Childs-Pugh A. On starting treatment, performance status (PS) was 0/1/2 in 49%/47%/4%. At the time of analysis, 22 (40%) patients were still alive and 7 (13%) patients were still on treatment. The median number of completed treatments was 3 with a median duration of treatment of 5.8m (95% CI: 2.0-9.6). Sorafenib was stopped due to toxicity in 11 (20%) patients. The median OS was 10.4m (95% CI: 5.6-15.2), with no significant different between PS 0 and PS 1 (11.1m v 9.8m, p=0.8). There was no association between alpha-fetoprotein and survival.


In our patient cohort we have observed similar results to those seen in the SHARP study, both in terms of duration of treatment and overall survival.